From the Journals

Cannabis use, childhood trauma correlated in schizophrenia patients


 

FROM SCHIZOPHRENIA RESEARCH

Childhood trauma was correlated with cannabis use in schizophrenia patients, but no significant interaction between the two factors was found, based on data from 366 individuals, including 295 with schizophrenia and 71 with schizoaffective disorder.

“Childhood trauma and cannabis consumption are among the most studied environmental risk factors for schizophrenia and are also considered to be risk-modifying factors,” wrote Grégoire Baudin of Université François-Rabelais in Tours, France, and colleagues (Schizophr Res. 2016;175:161-7).

Marijuana ©Doug Menuez/thinkstockphotos.com
To examine the relationship between CT and cannabis use in schizophrenia, the researchers assessed patients aged 15-84 years using several tools, including the Global Assessment of Functioning Scale, the Positive and Negative Symptoms Scale, and the Childhood Trauma Questionnaire.

Overall, the proportion of patients with a history of childhood trauma (CT) was not significantly different in those with and without cannabis use disorders, the researchers reported. However, CT was a significant predictor of the number of hospitalizations and of high scores on measures of excitement and emotional distress, and poor levels of function and quality of life.

The study was limited by not being representative of the schizophrenia population as a whole, the researchers noted. However, “our results emphasize the need for clinicians to systematically inquire about the traumatic history of patients with psychotic disorders, and consider trauma-focused therapy” for people with schizophrenia and for people at risk, the investigators added.

The researchers had no financial conflicts to disclose. The study was funded in part by the FondaMental Foundation, INSERM, and Investissements d’Avenir programs. Mr. Baudin has received a research grant from the FondaMental Foundation.

Find the full study here: doi: 10.1016/j.schres.2016.04.042.

Recommended Reading

Statement warns of drugs causing or exacerbating heart failure
MDedge Family Medicine
Childhood trauma, cannabis use disorders examined in schizophrenia
MDedge Family Medicine
Withdrawing risperidone spikes risk for psychotic relapse in hallucinating Alzheimer’s patients
MDedge Family Medicine
Antipsychotics in pregnancy pose no meaningful malformation risk
MDedge Family Medicine
Type 2 diabetes peer-led intervention in primary care tied to improved depression symptoms
MDedge Family Medicine
FDA adds lurasidone contraindication to HIV drug labels
MDedge Family Medicine
Psychiatric risks quantified in siblings of mental disorder patients
MDedge Family Medicine
Experts offer tips on anxiety, depression, and psychosis in Parkinson’s
MDedge Family Medicine
Cannabis use after first-episode psychosis may raise relapse risk
MDedge Family Medicine
Recognizing anti-NMDA receptor encephalitis psychosis on the psych ward
MDedge Family Medicine